8 March 2017 – Statement of Portugal – HRC 34 – Panel on Access to Medicines

On 8 March 2017, the Permanent Representative of Portugal, Ambassador Pedro Nuno Bártolo, made a powerful intervention at the Human Rights Council’s panel discussion on access to medicines. Portugal stressed that access to medicines is a fundamental element of the right to health and highlighted how the high prices of hepatitis C and cancer medicines made them unaffordable to large segments of the population in industrialized countries. Continue Reading

8 March 2017 – Statement of the European Union – HRC 34 – Panel on Access to Medicines

On 8 March 2017, the European Union (EU) delivered the following statement to the Human Rights Council’s panel discussion on Access to Medicines. As the Human Right Council imposed a strict two minute limit on interventions, the EU was not able to raise the following two questions contained at the end of its intervention.

I have two questions for the Panel.

Could the panellists suggest further measures to promote a holistic approach to access to medicines?

Continue Reading

8 March 2017 – Human Rights Council’s Access to Medicines panel set to discuss Report of UN HLP

On 8 March 2017, the Human Rights Council will convene a three hour Access to Medicines panel which will take place from 3 PM to 6 PM in Room XX of the Palais des Nations in Geneva. This panel is mandated by resolution 32/15 which passed at 32nd session of the Human Rights Council (June/July 2016). The resolution directed the Human Rights Council to convene an access to medicines panel at its 34th session in March 2017.

Continue Reading

1 March 2017 – WTO TRIPS Council – India’s intervention on the Report of the UN High-Level Panel on Access to Medicines

On 1 March 2017, India delivered the following statement during WTO TRIPS Council discussions on the United Nations Secretary-General’s High Level Panel Report on Access to Medicines.

Agenda item 12: the United Nations Secretary-General’s High Level Panel Report on Access to Medicines

Thank you Chairman.

At the outset, I would like to thank delegations of Brazil, China and South Africa who are also co-sponsors of this agenda item.

Continue Reading

1 March 2017 – WTO TRIPS Council – Brazil’s intervention on the Report of the UN High-Level Panel on Access to Medicines

On 1 March 2017, Brazil delivered the following statement during WTO TRIPS Council discussions on the Report of the United Nations High-Level Panel on Access to Medicines.

High Level Panel

As we all know, on 19 November 2015, United Nations Secretary General Ban Ki-moon announced the creation of the High-Level Panel on Innovation and Access to Health Technologies. Responding to this invitation, two chairs were designated to the panel, namely, Ms. Ruth Dreifuss, from Switzerland, and Festus Mogae, from Botswana.

Continue Reading

Ambassador Shameem Ahsan (Bangladesh) remarks on UN HLP – Opportunities to Advance Health Technology and Access

On 1 March 2017, Bangladesh, Brazil, India and South Africa, the Secretariat of the United Nations Secretary-General’s High-Level Panel on Access to Medicines and the South Centre convened a side event at the World Trade Organization (WTO) on the United Nations Secretary-General’s High Level Panel on Access to Medicines: Opportunities to Advance Health Technology and Access. This event took place on the margins of the WTO TRIPS Council.

Continue Reading

CDC FOIA shows US, WHO opposed request to discuss UNSG’s High-Level Panel on Access to Medicines Report at EB

Email records and memoranda released by the Centers for Disease Control (CDC) in response to a Knowledge Ecology International Freedom of Information Act (FOIA) request show that representatives of the World Health Organization (WHO) and the United States government opposed including India’s proposed agenda item on the United Nations Secretary-General’s High-Level Panel on Access to Medicines for discussion at the 140th WHO Executive Board meeting.

The full set of documents, which was released to KEI without redaction, are available here:

Continue Reading

MEP Lola Sánchez questions the European Commission: EU’s position on the UN High-Level Panel on Access to Medicines at WIPO

On 2 February 2017, MEP Lola Sánchez Caldentey (Podemos, Spain) tabled a series of written questions to the European Commission on the positions taken by the European Union at the World Intellectual Property Organization on 14 December 2016 in relation to the United Nations High-Level Panel on Access to Medicines (UN HLP)

Continue Reading

WTO Trade Policy Review: Members question the United States on compulsory licensing, Bayh-Dole, UNHLP & Section 337

In December 2016, during the twilight of President Barack Obama’s 44th presidency, the World Trade Organization (WTO) conducted a Trade Policy Review (TPR) of the United States of America. All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM). The TPRM takes place in the “Trade Policy Review Body which is actually the WTO General Council — comprising the WTO’s full membership — operating under special rules and procedures” (Source: WTO, Trade Policy Reviews: Brief Introduction).

Continue Reading

EB140: Statement of India on the Report of the United Nations High-Level Panel on Access to Medicines

On the morning of Monday, 23 January 2017, India delivered the following intervention at the 140th session of the World Health Organization’s Executive Board requesting the “explicit inclusion” of the United Nations Secretary-General’s High-Level Panel Report in the “provisional agenda of the EB140 as a separate agenda item under item 8.”

In making the case for the inclusion of the UN HLP in the WHO’s Executive Board deliberations, India articulate the following:

Continue Reading